[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
January 2, 2008

Arthritis Gene Therapy Trial Resumes

JAMA. 2008;299(1):28. doi:10.1001/jama.2007.37

A previously halted gene therapy trial for the treatment of rheumatoid arthritis has been given the green light to resume.

The trial, conducted by Seattle-based Targeted Genetics Corporation, was shut down this summer after Jolee Mohr, aged 36 years, died 3 weeks after receiving a gene therapy injection to treat inflammatory arthritis. Mohr enrolled in this phase 1/2 trial of a new gene therapy, which involved injections of an adeno-associated virus vector carrying a gene coding for a protein that inhibits tumor necrosis factor α (TNF-α), a proinflammatory cytokine. Mohr received an initial injection in her right knee in February and a second in July.

First Page Preview View Large
First page PDF preview
First page PDF preview
×